Perceptive Advisors’s Mereo BioPharma MREO Stock Holding History

Perceptive Advisors’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-876,961	Closed	-$1.97M	–	99
2025 Q1	$1.97M	Sell	876,961 -208,551	-19%	-$590K	0.07%	72
2024 Q4	$3.8M	Buy	1,085,512 +269,790	+33%	+$1.06M	0.1%	75
2024 Q3	$3.35M	Sell	815,722 -437,528	-35%	-$1.81M	0.07%	86
2024 Q2	$4.51M	Buy	+1,253,250	New	+$4.06M	0.11%	80
2021 Q3	–	Sell	-1,696,068	Closed	-$5.38M	–	150
2021 Q2	$5.38M	Sell	1,696,068 -4,303,932	-72%	-$14.4M	0.07%	123
2021 Q1	$20.2M	Buy	+6,000,000	New	+$21.2M	0.26%	78
2020 Q2	–	Sell	-179,419	Closed	-$187K	–	133
2020 Q1	$187K	Hold	179,419	–	–	﹤0.01%	107
2019 Q4	$588K	Hold	179,419	–	–	0.01%	102
2019 Q3	$534K	Hold	179,419	–	–	0.01%	96
2019 Q2	$452K	Buy	+179,419	New	+$785K	0.01%	97

Other funds holding MREO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors's MREO Position: Q2 2025 in Review

Perceptive Advisors sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 876,961 shares — an estimated $1.97M sold.

Perceptive Advisors first reported a position in MREO in Q2 2019 and held it in 10 quarters. The position peaked at $20.2M in Q1 2021. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

Perceptive Advisors reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
Perceptive Advisors sold 876,961 Mereo BioPharma shares in Q2 2025, an estimated $1.97M.
Perceptive Advisors first reported a position in Mereo BioPharma in Q2 2019 and held it in 10 quarters.
Perceptive Advisors's Mereo BioPharma position peaked at $20.2M in Q1 2021.
86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.